

1 **APPENDIX 1: Search strategies**

2

<b>PubMed</b>	
#1	"Ivermectin"[MeSH Terms] OR "Permethrin"[MeSH Terms] OR "benzyl benzoate"[All Fields] OR "azithromycin"[MeSH Terms] OR "hexachlorocyclohexane"[MeSH Terms] OR "hexachlorocyclohexane"[All Fields] OR "lindan"[All Fields] OR "lindane"[All Fields] OR "crotamiton"[Supplementary Concept] OR "crotamiton"[All Fields] OR "malathion"[MeSH Terms]
#2	"Mass Drug Administration"[MeSH Terms] OR "Chemoprevention"[MeSH Terms] OR "Antibiotic Prophylaxis"[MeSH Terms] OR "methoden daten anal"[Journal] OR "mda"[All Fields] OR "preventive chemotherapy"[All Fields]
#3	"Scabies"[MeSH Terms] OR "Sarcoptes scabiei"[MeSH Terms] OR "Impetigo"[MeSH Terms] OR "Pyoderma"[MeSH Terms] OR "impetig*"[All Fields]
#4	#1 AND #2 AND #3
<b>Embase via Scopus</b>	
#1	ivermectin OR permethrin OR "benzyl benzoate" OR malathion OR crotamiton OR lindane OR azithromycin
#2	"mass drug administration" OR chemoprevention OR "antibiotic prophylaxis" OR mda OR "preventive chemotherapy"
#3	scabies OR "sarcoptes scabiei" OR impetigo* OR pyoderma
#4	#1 AND #2 AND #3
<b>Web of Science</b>	
#1	TOPIC: (ivermectin) OR TOPIC: (permethrin) OR TOPIC: ("benzyl benzoate") OR TOPIC: (malathion) OR TOPIC: (lindane) OR TOPIC: (crotamiton)
#2	TOPIC: ("mass drug administration") OR TOPIC: (chemoprevention) OR TOPIC: (antibiotic prophylaxis) OR TOPIC: ("preventive chemotherapy")
#3	TOPIC: (scabies) OR TOPIC: ("sarcoptes scabiei") OR TOPIC: (impetig*) OR TOPIC: (pyoderma)
#4	#1 AND #2 AND #3
<b>Medline via EBSCOhost</b>	
#1	Scabies OR "Sarcoptes scabiei" OR Impetig* OR Pyoderma
#2	"Mass Drug Administration" OR Chemoprevention OR Antibiotic Prophylaxis OR MDA OR "preventive chemotherapy"
#3	"Ivermectin" OR "Permethrin" OR "benzyl benzoate" OR azithromycin OR lindane OR crotamiton OR "malathion"
#4	#1 AND #2 AND #3
<b>Cochrane Library</b>	
#1	Ivermectin OR permethrin OR "benzyl benzoate" OR malathion OR lindane OR crotamiton OR azithromycin
#2	mass drug administration OR antibiotic prophylaxis OR MDA
#3	Scabies OR "sarcoptes scabiei" OR impetigo OR pyoderma
#4	#1 AND #2 AND #3

3

4

5

**APPENDIX 2:** PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol\*

Section and topic	Item No	Checklist item	Self-Evaluation
<b>ADMINISTRATIVE INFORMATION</b>			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	Yes
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	Not applicable
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	<a href="#">CRD42020169544</a>
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	Provided
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	Provided
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	Not applicable
Support:			
Sources	5a	Indicate sources of financial or other support for the review	Provided
Sponsor	5b	Provide name for the review funder and/or sponsor	Not applicable
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	Not applicable
<b>INTRODUCTION</b>			
Rationale	6	Describe the rationale for the review in the context of what is already known	Provided
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	Yes
<b>METHODS</b>			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	Yes
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	Yes
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	Yes
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	Yes
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	Yes

Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	Yes
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	Yes
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	Yes
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	Yes
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	Yes
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I <sup>2</sup> , Kendall's $\tau$ )	Yes
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	Yes
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	Yes
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	Yes

**\* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

*From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.*

-End-